Caring Ambassadors

Hepatitis C Program Newsletter

www.HepCChallenge.org

January 2010

Clinical Trials, Cohort Studies, Pilot Studies

Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. Gramenzi A, Cursaro C, Margotti M, et al. World J Gastroenterol. 2009 Dec 21;15(47):5946-52.

http://www.ncbi.nlm.nih.gov/pubmed/20014458?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis c virus genotype 1 showing substitution of amino acid 70 in the core region. Ishii K, Shinohara M, Sawa M, et al. Kogame. Intervirology. 2009 Dec 3;53(2):105-110. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19955815?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C.

Hackl NJ, Bersch C, Feick P, et al. Scand J Gastroenterol. 2009 Dec 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hackl%20NJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract

Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon /ribavirin combination in patients chronically infected with HCV on methadone maintenance. Dimitroulopoulos D, Petroulaki E, Manolakopoulos S, et al. Eur J Gastroenterol Hepatol. 2009 Dec;21(12):1407-12.

http://www.ncbi.nlm.nih.gov/pubmed/19916203?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis c in Latino patients. Méndez-Navarro J, Chirino RA, Corey KE, et al. Dig Dis Sci. 2009 Dec 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19960257?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin.

Brixner DI, Ye X, Chu TC, Blumentals WA, Hassanein TI. J Health Syst Pharm. 2009 Dec 15;66(24):2171-8.

http://www.ncbi.nlm.nih.gov/pubmed/19966085?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Rustgi VK, Lee WM, Lawitz E, et al. Hepatology. 2009 Dec;50(6):1719-26.

http://www.ncbi.nlm.nih.gov/pubmed/19852040?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBV infection acquired in youth. Zampino R, Marrone A, Merola A, et al. J Med Virol. 2009 Dec;81(12):2012-20.

http://www.ncbi.nlm.nih.gov/pubmed/19856471?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. Dieterich DT, Rizzetto M, Manns MP. J Viral Hepat. 2009 Dec;16(12):833-43.

http://www.ncbi.nlm.nih.gov/pubmed/19889142?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

Basic and Applied Science, Pre-Clinical Studies

A Time-Resolved Fluorescence-Resonance Energy Transfer Assay for Identifying Inhibitors of Hepatitis C Virus Core Dimerization. Kota S, Scampavia L, Spicer T, et al. Assay Drug Dev Technol. 2009 Dec 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20035614?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Phospholipase A2 and Cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Su KP, Huang SY, Peng CY, et al. Biol Psychiatry. 2009 Dec 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20034614?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cells. Wintermeyer P, Gehring S, Eken A, Wands JR. J Viral Hepat.. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20002303?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

HIV/HCV Coinfection

Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV co-infected patients as a function of baseline CD4+ T-cell counts. Avidan NU, Goldstein D, Rozenberg L, et al. J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):452-8.

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Avidan%20NU%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

Risk factors for thrombocytopenia in HIV-infected persons in the era of potent anti-retroviral therapy. Marks KM, Clarke RM, Bussel JB, Talal AH, Glesby MJ. J Acquir Immune Defic Syndr. 2009 Dec;52(5):595-9.

http://www.ncbi.nlm.nih.gov/pubmed/19734800?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. Zhou S, Zhao Y, He Y, et al. J Acquir Immune Defic Syndr. 2009 Dec 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20032784?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Factors associated with the progression of hepatic fibrosis in end-stage kidney disease patients with hepatitis C virus infection. Becker VR, Badiani RG, Lemos LB, et al. Eur J Gastroenterol Hepatol. 2009 Dec;21(12):1395-9.

http://www.ncbi.nlm.nih.gov/pubmed/19525852?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment.

Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G. AIDS Patient Care STDS. 2009 Dec;23(12):993-9.

http://www.ncbi.nlm.nih.gov/pubmed/19929229?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-{alpha} and ribavirin in HIV/HCV co-infected patients. Vargas A, Berenguer J, Catalán P, et al. J Antimicrob Chemother. 2009 Dec 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20016018?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2

Complementary and Alternative Medicine

Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway.

Kim K, Kim KH, Kim HY, et al. FEBS Lett. 2009 Dec 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20026048?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=4

Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. Zhang H, Rothwangl K, Mesecar AD, et al. J Nat Prod. 2009 Dec 28;72(12):2158-2162.

http://www.ncbi.nlm.nih.gov/pubmed/19904996?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=8

Silibinin and related compounds are direct inhibitors of hepatitis c virus RNA-dependent RNA polymerase. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Gastroenterology. 2009 Dec 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19962982?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Prevalence of vitamin d deficiency in chronic liver disease. Arteh J, Narra S, Nair S. Dig Dis Sci. 2009 Dec 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19960254?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Epidemiology, Diagnostics, and Miscellaneous Works

Frequency of alcohol and smoking cessation counseling in hepatitis C patients among internists and gastroenterologists. Chandra T, Reyes M, Nguyen H, Borum M. World J Gastroenterol. 2009 Dec 21;15(47):6010-1.

http://www.ncbi.nlm.nih.gov/pubmed/20014469?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

Real-time quantitative assay for routine testing of HCV RNA in formalin-fixed, paraffin-embedded liver samples. Gruppioni E, Vasuri F, Fiorentino M, et al. Diagn Mol Pathol. 2009 Dec;18(4):232-8.

http://www.ncbi.nlm.nih.gov/pubmed/19861893?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=5

Public health impact of antiviral therapy for hepatitis C in the United States. Volk ML, Tocco R, Saini S, Lok AS. Hepatology. 2009 Dec;50(6):1750-5.

http://www.ncbi.nlm.nih.gov/pubmed/19824079?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=4

Europe's hepatitis challenge: defusing the "viral time bomb". Piorkowsky NY. J Hepatol. 2009 Dec;51(6):1068-73.

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Piorkowsky%20NY%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. Zeremski M, Dimova R, Brown Q, et al. J Infect Dis. 2009 Dec 1;200(11):1774-80.

http://www.ncbi.nlm.nih.gov/pubmed/19848607?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. Kanmura S, Uto H, Sato Y, et al. J Gastroenterol.. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20012107?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1